Phil Johnson

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania.

Orthovita, Inc. engages in the development and commercialization of synthetic biologically-active tissue engineering products for restoration of the human skeleton. The company was incorporated in 1992 and is headquartered in Malvern, PA.

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Founded in 2002, Othera Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing treatments for ophthalmic diseases. Othera is also engaged in the discovery of a novel set of orally available compounds to address severe medical conditions including inflammatory and oncology-related diseases.

Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

The Little Clinic LLC provides healthcare services. The firm diagnoses and treats minor illnesses for patients. The company was founded by Lisa Loscalzo in 2003 and is headquartered in Nashville, TN.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009.

The McKnight Endowment Fund for Neuroscience operates as a philanthropic organization. Its services include grantmaking, coalition-building and encouragement of strategic policy reforms. The company was founded by William L. McKnight in 1989 and is headquartered in Minneapolis, MN.

Invisible Sentinel, Inc. engages in food diagnostics. It offers food safety, wine, beer products such as veriflow for salmonella, listerria species and vinoBrett for breetanomyces bruxellensis, vinoPAL for pedicoccus and lactobacillus and veriflow custom solutions. The company was founded by Nicholas Siciliano and Benjamin Pascal in October 2006 and is headquartered in Philadelphia, PA.

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA.

Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY.

Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY.

Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA.

Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA.

Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA.

Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation.

viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation.

Intergalactic Therapeutics, Inc. is a gene therapy company based in Baltimore, MD. The company is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal c3dna molecules. The company uses a customized approach to focal therapeutic delivery using its lead delivery technology, the comet pulsed electric field system, and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. The company was founded by Michael D. Ehlers, and Theresa G. H. Heah has been the CEO of the company since 2023.

Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021.